NeuroScientific Biopharmaceuticals becomes Miro Sciences as it prepares for planned phase 2 trial
MSX: $0.054 +0.00% · MC: $16M
The company’s name change to Miro Sciences Ltd and ticker change from NSB to MSX took effect after shareholder approval and formal registration. The company says the new identity reflects its focus on its StemSmart cell therapy platform and preparations for a planned phase 2 trial in Australia and the United States for potential treatments for refractory Crohn’s disease.

Comments